Novartis AG (NVS)

83.15
1.10 1.30
NYSE : Health Care
Prev Close 82.08
Open 82.72
Day Low/High 82.44 / 83.27
52 Wk Low/High 69.89 / 104.75
Volume 1.06M
Avg Volume 1.79M
Exchange NYSE
Shares Outstanding 2.38B
Market Cap 197.38B
EPS 7.40
P/E Ratio 22.40
Div & Yield 2.72 (3.30%)

Latest News

Novartis Shares Slip Tuesday on Falling Profit

Novartis Shares Slip Tuesday on Falling Profit

Shares of the global healthcare company, Novartis, are down after it saw its profits fall in the second quarter.

Novartis (NVS) Stock Down on Profit Warning

Novartis (NVS) Stock Down on Profit Warning

Novartis (NVS) stock is lower in pre-market trading on Tuesday after cautioning that full-year profit could slide on more investments in its heart-failure drug.

European Markets Extend Losses as Brexit Shreds Confidence Index

European Markets Extend Losses as Brexit Shreds Confidence Index

A closely watched market sentiment indicator points to gloom in Germany and the euro area, while U.K. price growth picks up pace.

Novartis Second-Quarter Earnings, Revenue Fall Less Than Forecast

Novartis Second-Quarter Earnings, Revenue Fall Less Than Forecast

The pharmaceuticals company, led by CEO Joe Jiminez, had its first full quarter of generic competition for its Gleevec cancer drug.

3 Stocks Dragging In The Drugs Industry

3 Stocks Dragging In The Drugs Industry

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Shire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta

Shire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta

At least one company follower believes the divestiture of Shire's Neurology division for as much as $13 billion would be a logical next move.

X(encor) Marks the Spot For Potential Gains

X(encor) Marks the Spot For Potential Gains

You have to be impressed by the breadth of XNCR's pipeline and significant partnerships with major players.

Assessing the Impact of Juno's Cancer CAR-T Stumble on Biotech Stocks

Assessing the Impact of Juno's Cancer CAR-T Stumble on Biotech Stocks

Juno Therapeutics reminds investors yet again that the business of biotech -- developing new medicines that are effective and reasonably safe -- is hard to get right.

These 5 Big Stocks Are Breaking Out This Summer

These 5 Big Stocks Are Breaking Out This Summer

Here's a technical look at how to trade some of the biggest stocks on the market right now.

'Mad Money' Lightning Round: You Should Be Buying Visa

'Mad Money' Lightning Round: You Should Be Buying Visa

Cramer says Wynn is fantastic but he's avoiding Valeant.

Jim Cramer's 'Mad Money' Recap: Thank the Short-Sellers for This Continued Rally

Jim Cramer's 'Mad Money' Recap: Thank the Short-Sellers for This Continued Rally

When short-sellers get caught leaning the wrong way, that's a recipe for explosive moves to the upside, Cramer says.

Analysts' Actions -- Comerica, Coach, Harman, Oracle and More

Analysts' Actions -- Comerica, Coach, Harman, Oracle and More

Here are Wednesday's top research calls, including downgrades for Comerica, Coach and Harman, and an upgrade for Oracle.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: APLP, DCI, DWRE, ISIL, MBT, NVS, STC Downgrades: AMG, COH, EQS, GIG, LECO, MITK, NEWM, TRNC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Trade-Ideas: Novartis (NVS) Is Today's Pre-Market Leader Stock

Trade-Ideas: Novartis (NVS) Is Today's Pre-Market Leader Stock

Trade-Ideas LLC identified Novartis (NVS) as a pre-market leader candidate

'Brexit': Stocks to Avoid on June 24

'Brexit': Stocks to Avoid on June 24

Stay away from banks, but pharmaceuticals and tech stocks look good, analysts say.

Meet the Marijuana Industry Money-Man, Rob Hunt of Tuatara Capital

Meet the Marijuana Industry Money-Man, Rob Hunt of Tuatara Capital

It was all about the green at this week's Cannabis World Congress in New York.

Jim Cramer's 'Mad Money' Recap: The Bull Is Napping

Jim Cramer's 'Mad Money' Recap: The Bull Is Napping

The rally has been strong and the bull market is taking a deserved rest, Cramer says.

3 Stocks Pulling The Health Care Sector Downward

3 Stocks Pulling The Health Care Sector Downward

TheStreet highlights 3 stocks pushing the health care sector lower today.

What You Need to Know About Biotech IPOs This Year

What You Need to Know About Biotech IPOs This Year

Here's the lowdown on the biotech companies that have come public this year.

Pharma Giant Novartis Is a Great Bargain for Investors

Pharma Giant Novartis Is a Great Bargain for Investors

Novartis has had to cope with the expiration of some patents, but it should benefit from its varied products and significant investment in research and development.

Endo Could Be the Next Activist Target in Generics

Problems with mesh products and high leverage might scare away a potential buyer. 

Analysts Differ On Impact Of Valeant's Rejected Takeover Bid

Analysts Differ On Impact Of Valeant's Rejected Takeover Bid

Shares of Valeant Pharmaceuticals jumped following last night's report by The Wall Street Journal saying that the company rejected a joint takeover approach from Takeda Pharmaceuticals and TGP Capital.

Finding the path forward

Finding the path forward

Huge uncertainty hangs over the markets in 2016

Heavy Trading On Novartis (NVS) Before Market Open

Heavy Trading On Novartis (NVS) Before Market Open

Trade-Ideas LLC identified Novartis (NVS) as a pre-market mover with heavy volume candidate

Ziopharm Subpar Cancer Therapies Can't Support Lofty Market Valuation

Ziopharm Subpar Cancer Therapies Can't Support Lofty Market Valuation

Ziopharm is its own mini biotech bubble, held aloft unjustifiably because of its interlocking relationship with Intrexon, the synthetic biology company majority-owned by R.J. Kirk.

Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted

Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Global Pharma Players Likely to Flock to Medivation

Global Pharma Players Likely to Flock to Medivation

AstraZeneca, Bayer, Eli Lilly and Merck are just a few of the names that may join a bidding war for the cancer drug maker, analysts say.

Jim Cramer -- Valeant Has Too Many 'What Ifs' Right Now

Jim Cramer -- Valeant Has Too Many 'What Ifs' Right Now

New Chairman and CEO Joe Papa can't stop the world from gunning for Valeant.